Lv M - Search Results

1

Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy.

Ma Y, Lv M, Yuan P, Chen X, Liu Z. Ma Y, et al. Among authors: lv m. BMC Cancer. 2023 Mar 4;23(1):208. doi: 10.1186/s12885-023-10683-y. BMC Cancer. 2023. PMID: 36870942 Free PMC article.

2

Long intergenic noncoding RNA 00641 inhibits breast cancer cell proliferation, migration, and invasion by sponging miR-194-5p.

Mao Q, Lv M, Li L, Sun Y, Liu S, Shen Y, Liu Z, Luo S. Mao Q, et al. Among authors: lv m. J Cell Physiol. 2020 Mar;235(3):2668-2675. doi: 10.1002/jcp.29170. Epub 2019 Sep 6. J Cell Physiol. 2020. PMID: 31490021

3

Knockdown of LINC00665 inhibits proliferation and invasion of breast cancer via competitive binding of miR-3619-5p and inhibition of catenin beta 1.

Lv M, Mao Q, Li J, Qiao J, Chen X, Luo S. Lv M, et al. Cell Mol Biol Lett. 2020 Sep 24;25:43. doi: 10.1186/s11658-020-00235-8. eCollection 2020. Cell Mol Biol Lett. 2020. PMID: 32983239 Free PMC article.

4

Neoadjuvant docetaxel with or without carboplatin plus dual HER2 blockade for HER2-positive breast cancer: a retrospective multi-center Chinese study.

Lv M, Guo H, Wang C, Tian P, Ma Y, Chen X, Luo S. Lv M, et al. Gland Surg. 2020 Dec;9(6):2079-2090. doi: 10.21037/gs-20-791. Gland Surg. 2020. PMID: 33447559 Free PMC article.

5

Impact of Ipsilateral Supraclavicular Lymph Node Dissection (ISLND) for Breast Cancer Patients and a Nomogram for Predicting Ipsilateral Supraclavicular Pathological Complete Response (ispCR).

Lv M, Li J, Guo H, Wang C, Tian P, Ma Y, Chen X, Luo S. Lv M, et al. Ann Surg Oncol. 2021 Sep;28(9):5098-5109. doi: 10.1245/s10434-020-09548-6. Epub 2021 Feb 17. Ann Surg Oncol. 2021. PMID: 33598861

6

Correction to: Impact of Ipsilateral Supraclavicular Lymph Node Dissection (ISLND) for Breast Cancer Patients and a Nomogram for Predicting Ipsilateral Supraclavicular Pathological Complete Response (ispCR).

Lv M, Li J, Guo H, Wang C, Tian P, Ma Y, Chen X, Luo S. Lv M, et al. Ann Surg Oncol. 2021 Dec;28(Suppl 3):871. doi: 10.1245/s10434-021-09841-y. Ann Surg Oncol. 2021. PMID: 33738721 No abstract available.

7

Evaluation of whether adjuvant chemotherapy can be safely omitted for older female patients with ER-positive, HER2-negative N1 breast cancer: a study based on the SEER database.

Lv M, Yuan P, Ma Y, Tian P, Chen X, Liu Z. Lv M, et al. Ann Transl Med. 2021 Jul;9(13):1082. doi: 10.21037/atm-21-3097. Ann Transl Med. 2021. PMID: 34422994 Free PMC article.

8

Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database.

Wu J, Lv M, Yuan P, Ma Y, Tian P, Li L, Wang C, Lu Z, Yan M, Chen X, Liu Z. Wu J, et al. Among authors: lv m. Gland Surg. 2022 Aug;11(8):1341-1355. doi: 10.21037/gs-22-409. Gland Surg. 2022. PMID: 36082084 Free PMC article.

9

Impact of residual disease biomarkers on the prognosis of HER2-positive breast cancer following neoadjuvant therapy.

Ma Y, Zhu M, Lv M, Yuan P, Chen X, Liu Z. Ma Y, et al. Among authors: lv m. Cancer Med. 2023 May;12(10):11293-11304. doi: 10.1002/cam4.5839. Epub 2023 Mar 23. Cancer Med. 2023. PMID: 36951436 Free PMC article.

10

Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy.

Ma Y, Zhu M, Zhang J, Lv M, Chen X, Liu Z. Ma Y, et al. Among authors: lv m. Cancer Res Treat. 2023 Oct;55(4):1210-1221. doi: 10.4143/crt.2022.1633. Epub 2023 Apr 4. Cancer Res Treat. 2023. PMID: 37024094 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,904 results

Search Page

Filters